WebAug 23, 2024 · This year, Foghorn also began a Phase I trial of its BRG1 and BRM inhibitor FHD-286 in metastatic uveal melanoma. The company is also studying FHD-286 in advanced hematologic cancers, including acute myeloid leukemia and myelodysplastic syndromes. Filed under Cancer WebMar 9, 2024 · Foghorn Therapeutics Provides 2024 Outlook and Full Year 2024 Corporate Update Published: Mar 09, 2024 - Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial safety and efficacy data expected in the first half of 2024
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM …
WebApr 13, 2024 · BAF inhibition with a dual inhibitor of BRG1/BRM modulates transcriptional regulator SPI1 in preclinical in vitro and in vivo models, supporting a mechanistic basis for the clinical development of ... WebMar 9, 2024 · Foghorn Therapeutics Provides 2024 Outlook and Full Year 2024 Corporate Update. March 9, 2024. Download PDF. - Phase 1 dose escalation study of FHD-286, a … chad meme vector
Foghorn Therapeutics to Present Preclinical Data from Its …
WebBrompheniramine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: drowsiness. dry mouth, nose, and throat. nausea. headache. … WebDec 13, 2024 · For the BRM-selective program and the additional undisclosed target program, Foghorn will lead discovery and early research activities, while Lilly will lead development and commercialization... WebApr 11, 2024 · Foghorn® Therapeutics Inc. announced that preclinical data from two of its protein degrader programs, Selective EP300 and Selective CBP, and preclinical data for its BRG1/BRM inhibitor, FHD-286, will be presented at the 2024 American Association for Cancer Research Annual Meeting. hansen company inc